Skip to main content
SpringerLink
Log in

Semaglutid versus Dulaglutid: SUSTAIN 7 – Eine Vergleichsstudie bei Patienten mit Diabetes mellitus Typ 2

Semaglutide versus dulaglutide: SUSTAIN 7—a head-to-head trial in patients with type 2 diabetes

  • Journal Club
  • Published:
Der Diabetologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Drucker DJ (2016) The cardiovascular biology of glucagon-like peptide-1. Cell Metab 24:15–30. https://doi.org/10.1016/j.cmet.2016.06.009

    Article  CAS  PubMed  Google Scholar 

  2. Pratley RE, Aroda VR, Lingvay I et al (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(18)30024-X

    PubMed  Google Scholar 

  3. European Medicines Agency (2018) Find medicine – Ozempic. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004174/human_med_002211.jsp&mid=WC0b01ac058001d124. Zugegriffen: 8. März 2018

    Google Scholar 

  4. ClinicalTrials.gov (2018) Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) – Full Text View. https://clinicaltrials.gov/ct2/show/NCT01394952. Zugegriffen: 8. März 2018

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department für Innere Medizin, Neurologie und Dermatologie, Klinik und Poliklinik für Endokrinologie und Nephrologie, Universitätsklinikum Leipzig, Liebigstr. 20, 04103, Leipzig, Deutschland

    M. Federbusch

Authors
  1. M. Federbusch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Federbusch.

Ethics declarations

Interessenkonflikt

M. Federbusch gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Federbusch, M. Semaglutid versus Dulaglutid: SUSTAIN 7 – Eine Vergleichsstudie bei Patienten mit Diabetes mellitus Typ 2. Diabetologe 14, 177–179 (2018). https://doi.org/10.1007/s11428-018-0323-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-018-0323-1

Search

Navigation